Jack Slevin
Stock Analyst at Jefferies
(4.18)
# 1,472
Out of 4,455 analysts
39
Total ratings
62.5%
Success rate
27.5%
Average return
Main Sectors:
Stocks Rated by Jack Slevin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGL agilon health | Upgraded: Buy | $28 → $48 | $119.25 | -59.75% | 8 | May 7, 2026 | |
| MD Pediatrix Medical Group | Maintained: Buy | $21 → $27 | $24.68 | +9.40% | 4 | Apr 20, 2026 | |
| CVSA Covista | Maintained: Buy | $175 | $127.53 | +37.22% | 3 | Apr 2, 2026 | |
| USPH U.S. Physical Therapy | Rated: Buy | $102 | $68.78 | +48.30% | 1 | Mar 9, 2026 | |
| PRVA Privia Health Group | Reiterated: Buy | $30 → $32 | $25.57 | +25.15% | 6 | Feb 26, 2026 | |
| CCRN Cross Country Healthcare | Maintained: Hold | $19 → $8.65 | $13.22 | -34.57% | 3 | Dec 4, 2025 | |
| ASTH Astrana Health | Maintained: Buy | $44 → $37 | $44.51 | -16.87% | 8 | Nov 25, 2025 | |
| AMN AMN Healthcare Services | Maintained: Hold | $22 → $21 | $32.76 | -35.90% | 4 | Aug 13, 2025 | |
| TOI The Oncology Institute | Maintained: Buy | $2.5 → $2 | $5.39 | n/a | 2 | Jun 10, 2024 |
agilon health
May 7, 2026
Upgraded: Buy
Price Target: $28 → $48
Current: $119.25
Upside: -59.75%
Pediatrix Medical Group
Apr 20, 2026
Maintained: Buy
Price Target: $21 → $27
Current: $24.68
Upside: +9.40%
Covista
Apr 2, 2026
Maintained: Buy
Price Target: $175
Current: $127.53
Upside: +37.22%
U.S. Physical Therapy
Mar 9, 2026
Rated: Buy
Price Target: $102
Current: $68.78
Upside: +48.30%
Privia Health Group
Feb 26, 2026
Reiterated: Buy
Price Target: $30 → $32
Current: $25.57
Upside: +25.15%
Cross Country Healthcare
Dec 4, 2025
Maintained: Hold
Price Target: $19 → $8.65
Current: $13.22
Upside: -34.57%
Astrana Health
Nov 25, 2025
Maintained: Buy
Price Target: $44 → $37
Current: $44.51
Upside: -16.87%
AMN Healthcare Services
Aug 13, 2025
Maintained: Hold
Price Target: $22 → $21
Current: $32.76
Upside: -35.90%
The Oncology Institute
Jun 10, 2024
Maintained: Buy
Price Target: $2.5 → $2
Current: $5.39
Upside: n/a